Wells Fargo raised the firm’s price target on Sabra Health Care (SBRA) to $21 from $20 and keeps an Overweight rating on the shares. The firm says that despite a few high-profile exceptions, most REITs delivered Q3 2025 earnings and outlooks reflecting healthy operating conditions despite macro and labor market concerns.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SBRA:
- Sabra Health Care initiated with a Neutral at UBS
- Hold Rating for Sabra Healthcare REIT Amidst Balanced Valuation and Strategic Challenges
- Sabra Health Care REIT Reports Strong Q3 2025 Results
- Sabra Healthcare REIT’s Optimistic Earnings Call Analysis
- Sabra Healthcare REIT: Balancing Strong FAD Performance with Capital Cost Challenges